Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorTianjin Medical University
About this trial
To evaluate the potential usefulness of 68Ga/18F-Pentixafor/Pentixather positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients
18F-FDG PET/CT within two weeks
signed written consent.
Disqualifiers
pregnancy
breastfeeding
known allergy against Pentixafor
Trial design
Design model
Single group
Treatments tested in this trial
CXCR4 PET/CT Imaging
Diagnostic testEach subject receive a single intravenous injection of 68Ga/18F-Pentixafor/Pentixather, and undergo PET/CT imaging within the specificed time.
Treatment groups
200 Participants
are divided into 1 treatment groupGroup A: CXCR4 PET/CT ImagingExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Standardized uptake value (SUV)
Standardized uptake value (SUV) of FAPI for each target lesion of subject or suspected primary tumor or/and metastasis.
Time frame
30 daysSecondary outcomes
1
Diagnostic efficacy
The sensitivity, specificity and accuracy of FAPI PET/CT were calculated.
Time frame
30 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Tianjin Medical University
Lead sponsor
Tianjin Medical University General Hospital
Collaborator
Source ClinicalTrials.gov